FDA Greenlights Key HARMONIC Phase 2 Trial Amendments for LP-300, Citing Promising Early Data

summarizeSummary

Lantern Pharma received favorable FDA feedback on its HARMONIC Phase 2 trial for LP-300, allowing key protocol amendments and highlighting promising early clinical data, which de-risks the program.

check_boxKey Events

• FDA Type C Meeting Success

  The FDA raised no objections to three key protocol amendments for the HARMONIC Phase 2 clinical trial of LP-300, marking a significant de-risking milestone.

• Trial Design De-Risked

  Approved amendments include enriching enrollment for EGFR Exon 21 L858R patients, extending LP-300 dosing to 8 cycles, and transitioning to a single-arm study design, which is expected to accelerate enrollment.

• Promising Early Clinical Data

  Preliminary HARMONIC™ data (n=31) show an 8.4-month median Progression-Free Survival (mPFS) and durable responses exceeding 2 years in select L858R-mutant patients.

• Superior Tolerability Profile

  LP-300 combined with chemotherapy demonstrated markedly cleaner safety compared to a competitor (amivantamab + chemo), with significantly lower rates of serious treatment-related adverse events and infusion reactions.

auto_awesomeAnalysis

Lantern Pharma disclosed detailed positive outcomes from its FDA Type C meeting for the HARMONIC Phase 2 trial of LP-300. The FDA raised no objections to critical protocol amendments, including enriching enrollment for EGFR Exon 21 L858R patients, extending dosing, and transitioning to a single-arm design. This regulatory clarity, combined with promising preliminary data showing an 8.4-month median PFS and superior tolerability, significantly de-risks the trial and provides a clearer path towards potential registration for a key asset, which is crucial for the company given its recent 'going concern' warning.